# Jubilant Pharmova Ltd (JUBLPHARMA)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹957.35
Day Change: -1.67%
52W High: ₹1248
52W Low: ₹786.05
Market Cap: ₹16,043 Cr

## Valuation
P/E: 37.2
P/B: 2.44
EPS: ₹27.23
Book Value: ₹415.87
Dividend Yield: 0%

## Returns
1Y Return: -9.2%

## Profitability
ROE: 0%
ROCE: 11.59%
Debt/Equity: 0.44
Revenue Growth: 16.5%
Profit Growth: -44.7%
EBITDA Margin: 13.52%
Operating Margin: 7.95%

## About
Jubilant Pharmova Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Jubilant Pharmova Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-06-08T20:00:07.519Z
Price History Updated: 2026-06-08T18:00:34.788Z
Latest Price History Date: 2026-06-08
Technicals Updated: 2026-06-08T18:00:34.788Z
Quant Updated: 2026-06-08T18:00:34.788Z
Sentiment Updated: 2026-06-08T18:00:34.788Z
Financials Status: current
Financials Updated: 2026-05-18T09:31:44.286Z
Financials Last Attempt: 2026-05-18T09:31:44.286Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹5762 Cr
Operating Profit: ₹999 Cr (OPM 17%)
Net Profit: ₹138 Cr
Tax: ₹207 Cr

## Annual P&L History
Mar 2015: Rev ₹5762Cr | PAT ₹138Cr | OPM 17%
Mar 2016: Rev ₹5751Cr | PAT ₹-40Cr | OPM 11%
Mar 2017: Rev ₹5749Cr | PAT ₹387Cr | OPM 22%

## Balance Sheet (Mar 2015)
Total Assets: ₹8864 Cr
Total Liabilities: ₹8864 Cr
Borrowings: ₹4395 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Priyavrat  Bhartia MBA, MD & Director
- Arjun Shanker Bhartia, Joint MD & Director
- Arun Kumar Sharma B.Sc., C.A., CFO & Group Treasurer
- Prakash Chandra Bisht B.Com., CA, Executive VP of Group Accounts
- Sanjay  Gupta A.C.M.A., B.Com., L.L.B., Executive VP & Head of Legal

---
Source: rupiya.io/stocks/jublpharma
Disclaimer: For research and education only. Not investment advice.